affected are the medium size arteries, most notably the coronary arteries, resulting in coronary artery lesions (CALs) in 25% of untreated patients. 1 KD is now the leading cause of acquired heart disease in children. 1 Standard therapy for patients with acute KD is treatment with intravenous immunoglobulin (IVIG) and aspirin which reduces the risk of CALs from 25% to 5%. 2 However, studies have shown that 10-38% of patients fail to respond or develop recrudescent fever; these patients are characterized as IVIG resistant and are at highest risk in developing coronary artery aneurysms and require additional therapy to interrupt the inflammatory process. 3, 4 In Japan, effective scoring systems have been developed to identify KD patients at high risk for IVIG resistance. [5] [6] [7] Intensified therapy with prednisolone and IVIG in these high-risk patients improved coronary artery outcomes in the study populations. 8, 9 Efforts to identify a subset of "high risk" KD patients in more heterogeneous populations like the United States, however, have been unsuccessful. 4 , 10 We previously demonstrated that 80% of children with KD who develop CALs have those lesions present at time of diagnosis. 11 We postulate that these patients likely represent a group that may benefit from more aggressive initial therapy. 11 Infliximab, a tumor necrosis factor-α antagonist, has been shown to be safe, well tolerated, and is used in some centers to treat IVIG-resistant KD.
12-14 A prior study using infliximab plus IVIG as an intensification of initial therapy in KD patients has been shown to decrease fever duration, some markers of inflammation and left anterior descending (LAD) coronary artery Z scores. 15 In this study, we compared KD patients with CALs at initial presentation treated with standard therapy with those treated with standard therapy plus infliximab to see if there was a reduction in IVIG resistance, decrease in length of stay and differences in CALs changes between groups.
PATIENTS AND METHODS

Patients
All children admitted to Children's Hospital Colorado from January 2009 to July 2016 and diagnosed with KD by pediatric infectious disease specialist were eligible for the study. Patients were included if they had CALs present at time of diagnosis on their first echocardiogram before treatment. Medical records were retrospectively reviewed using a standardized form to collect demographic data, clinical information, echocardiogram findings and laboratory test results. CALs were defined as a Boston Z score ≥2.5 in the right coronary artery (RCA) or LAD coronary artery. Coronary artery aneurysms were defined as Boston Z score ≥5.0. Day 1 of illness was defined as the first day of fever. IVIG resistance was defined as a recrudescence of fever (temperature, ≥38.3°C) from 36 hours to 7 days after completion of IVIG infusion. 
Statistical Analysis
Data cleaning and statistical analysis were conducted using R version 3.3.2. Linear mixed models were fit using the R package nlme. P values in Table 1 are the result of t tests when mean and standard deviation are reported, Wilcoxon rank-sum tests for median and interquartile interval and χ 2 or Fisher's exact test for counts and percentages depending on the minimum expected cell count. The effect of treatment on length of stay was assessed with log-normal regression. The effect of treatment on need for second therapy was assessed primarily for those needing additional therapy because of fever and for all reasons as a sensitivity analysis. Logistic regression was used to assess these binary outcomes. The effect of treatment on C-reactive protein pre-and post-treatment was assessed using linear mixed models, with a random intercept to account for correlation between the 2 measures. C-reactive protein was log transformed because of skewness. Finally, the effect of treatment on CAL in both the LAD and RCA arteries was assessed using linear mixed models. LAD and RCA CAL measures were collected at baseline and each patient follow-up visit, with an average of 4.8 measurements per patient. To account for variation in the timing of the CAL measurement and correlation between a patient's measurements, time was treated as continuous and a spatial exponential covariance structure was implemented using days from baseline echocardiogram as the distance measure. Additionally, we fit a combined model including both artery measures in 1 outcome, modeling correlation by nesting artery within patient. Coronary artery aneurysms were compared between 2 treatment groups at baseline, 2 and 6 weeks. All regression models were adjusted for age and gender. Because of the inclusion criteria being defined as RCA or LAD Z score of ≥2.5, the CAL models were also adjusted for which artery was measured as abnormal (RCA, LAD or both). A significance level of 0.05 was used for hypothesis tests.
RESULTS
During the study period, 429 patients were diagnosed with KD and treated at our institution. Sixty-nine (16%) of these patients had CALs present at diagnosis before treatment and were included in the study. There were 34 KD patients with CALs treated with IVIG and 35 KD patients with CALs treated with IVIG plus infliximab. All patients received aspirin. Thirty (89%) of the patients treated with IVIG and aspirin alone (IVIG alone group) were treated before 2014, and 32 (89%) of patients treated with IVIG, aspirin and infliximab (IVIG plus infliximab group) were treated after 2014 (Fig. 1) . Except for the fact that patients in the IVIG alone group were more likely to have been diagnosed before 2014, there were no differences in demographic, clinical or laboratory characteristics between groups ( ALT indicates alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GGT, gamma-glutamyl transferase; HPF, high power field; IQR, interquartile range; PICU, pediatric intensive care unit; WBC, white blood cells.
( Table 2 ). Two patients in each group received an additional therapy because of worsening CALs (not because of return of fever). Including these patients in the analysis did not significantly change the results. Overall, the odds of needing a second treatment because of persistence or recrudescence of fever was 8.1 times higher in the treatment group that only received IVIG and aspirin (95% confidence interval: 2.26-37.55; P = 0.003). This effect was independent of age and sex (data not shown). Of the 15 patients who received initial therapy with IVIG alone, 9 received a second dose of IVIG (6 responded and 3 required a third therapy) and 6 received infliximab (4 responded, 1 required a third therapy, and 1 required 2 additional [third and fourth] therapies). The 1 patient who required a fourth therapy was the only patient who received steroids. Of the 4 patients in the IVIG plus infliximab group who required a second therapy, 2 were treated with a second dose of IVIG and 2 were treated with infliximab; none of them required a third therapy.
Although not statistically significant, there was a trend toward shorter length of stay in the IVIG plus infliximab group (Table 2 ). There were no significant differences between treatment groups in hospital costs (data not shown), fall in C-reactive protein 24 hours post-treatment, nor in overall improvement of coronary artery Z scores at 2 and 6 weeks (Table 3) .
Although not statistically significant, there were more adverse events noted in the IVIG group (Table 2) . Two patients in the IVIG-only group experienced infusions reactions, 2 develop aseptic meningitis and 2 developed hemolytic anemia requiring blood transfusions. One of the cases of aseptic meningitis and both cases of hemolytic anemia developed after receipt of the second dose of IVIG. One infusion reaction occurred in the IVIG plus infliximab group. No patients presented with a serious bacterial or viral infection in the 3 months after treatment in either group. Retreatment and adverse events were tested with Fisher's exact tests. Length of stay was modeled with log-normal regression and CRP was log transformed and modeled with a linear mixed model. CI indicates confidence interval; CRP, C-reactive protein.
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DISCUSSION
Our study suggests that IVIG and aspirin plus infliximab as initial therapy for KD patients with CALs reduces the need for additional second-line therapy, thus decreasing the number of patients who are IVIG resistant. This is important as previous studies have demonstrated that KD patients who are IVIG resistant and have prolonged inflammation are at higher risk for CALs and aneurysms. 17 Furthermore, coronary artery dilatation or aneurysms may lead to stenosis or thrombosis as these patients for which there are currently no known treatments. 18 Therefore, it is imperative that KD patients with CALs at presentation be treated with aggressive initial therapy to diminish the inflammation associated with this disease and improve outcomes in this population.
There have been many efforts to identify high-risk KD patients who have a high likelihood of being IVIG resistant to treat these patients more aggressively and decrease the incidence of CALs. Prior studies from Japan have resulted in successful scoring systems including the Egami, Sano and Kobayashi scores to predict IVIG resistance. 6, 7, 19 Unfortunately, these scoring systems have low sensitivity in heterogeneous US populations and efforts to identify "high-risk," IVIG-resistant patients in North American cohorts have been unsuccessful. [4] [5] [6] [7] [8] 10, 19 Our present study demonstrates that children with KD who have CALs at diagnosis have a high likelihood of IVIG resistance, as almost half of those in the IVIG alone group required a second therapy. Furthermore, a recent US study found that having a Z score ≥2 at presentation was predictive of future development of coronary artery aneurysms. 20 Our data combined with this recent study support targeting this group of patients (those with CALs present at diagnosis) for more aggressive initial therapy.
The first use of infliximab for the treatment of KD was reported in 2004 by Weiss et al 21 and was subsequently used in 1% of the 4811 IVIG-resistant cases. 22 Infliximab is a chimeric monoclonal antibody that binds with high affinity to tumor necrosis factor-α which is found in high levels in acute KD patients. Tremoulet et al 15 demonstrated in a randomized double-blind, placebo-controlled trial that infliximab plus IVIG as initial intensified therapy resulted in shorter fever duration and faster normalization of inflammatory markers. They also demonstrated that infliximab as an intensification of initial therapy decreased LAD Z scores at week 2, but no differences were seen at week 5. 15 Our findings differ as their study did not demonstrate a decrease in the number of IVIG-resistant patients with use of infliximab. 15 This may reflect a difference in the patient study populations. Our study was limited to patients who had CALs at initial presentation, whereas study by Tremoulet et al 15 randomized all KD patients with or without CALs. As such, the study by Tremoulet et al 15 was likely underpowered to detect a difference in this important outcome. Together these studies support the use of infliximab as adjunctive therapy in patients with KD and provide an alternative option to the use of corticosteroids.
Prior studies have demonstrated the safety of 1 dose of infliximab in children with KD. 12, 14, 15 Similarly, we did not observe any adverse events in our patients in the IVIG plus infliximab group. Nevertheless, infectious complications have been reported in patients with underlying autoimmune diseases who have been treated with infliximab, usually with multiple courses of therapy. 23 Furthermore, patients with autoimmune diseases are often treated with other immunosuppressive agents concurrently with infliximab. To date, infectious complications have not been reported in KD patients treated with 1 dose of infliximab in KD patients. In this study, more adverse events were noted in the IVIG group compared with the infliximab group.
Our study has several limitations. This study is a singlecenter retrospective study. Although we used a standardized data collection form, clinical evaluations may have differed depending on the individual providers who were caring for these children. Despite efforts to standardize therapy with time, the treatment of KD patients was at the discretion of the treating providers. Most patients treated with IVIG alone presented in the earlier years of this study. Therefore, if there is an infectious KD agent, it is possible that a different strain of the KD etiologic agent could have been circulating in the early versus later time period resulting in different responses to the 2 therapies. Similarly, there may have been some difference between the 2 group that occurred during these 2 time periods not accountable for in our analysis. Finally, because of the relatively small sample size, the study was likely underpowered to detect differences in CALs outcomes between treatment groups and for this endpoint further investigations are needed. 
